Glaxo Group Limited v. Genentech Inc and Biogen Idec Inc, Court of Appeal, London, UK, 31 January 2008, Case No.  EWCA Civ 23, with thanks to Marc Döring and Rowan Freeland, Simmons & Simmons
In this decision, the Court of Appeal has given important guidance on the circumstances in which should the Patents Court should exercise its inherent power to stay patent revocation proceedings pending the final outcome of opposition proceedings at the European Patent Office (EPO).
Read the first instance decision (in English) here.Read the appeal decision (in English) here.
Read the extended summary (provided by Rowan Freeland) here.